MEDSIR reports PHERGain and PHERGain-2 trial results for breast cancer

MEDSIR has reported data from the PHERGain and PHERGain-2 trials, which focused on targeted therapies in early HER2-positive breast cancer. PHERGain enrolled 356 patients from 45 hospitals in seven European countries, with five-year survival data. The studies focused on targeted therapies in early HER2-positive breast cancer. Credit: Thomas Andreas / Shutterstock.com. MEDSIR has reported data from the PHERGain and PHERGain-2 trials, which focused on targeted therapies in early human epidermal growth factor receptor 2 (HER2)-positive breast cancer. These studies aim to identify patients who may safely forgo conventional chemotherapy, reducing treatment toxicity and improving quality of life. LOA and PTSR…

Source: Clinical Trials Arena